Therapeutic Solutions International (TSI) was founded with a mission to develop and produce high-quality nutraceuticals aimed at enhancing immune system function. The company’s core vision is to leverage advanced scientific research to create products that improve health outcomes, particularly in the areas of cancer treatment, infection recovery, and illness prevention. One of their flagship products is NanoStilbene™, a nanoemulsion of nanoparticle pterostilbene designed for enhanced bioavailability.

Notable figures associated with TSI include Raymond Oliver, a veteran in public company management, who has been appointed as Chairman of Campbell Neurosciences, a subsidiary focused on immunology-based suicide prevention. The company has achieved significant milestones, including receiving a Notice of Allowance for a landmark patent covering cellular therapy for lung diseases. TSI's impact is marked by its innovative approach to nutraceuticals and its contributions to immune system-based therapies.